Sionna Therapeutics Inc. (SION)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment
Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million
33,356 shares sold for a transaction value of $1,486,009.80 on Dec. 24, 2025. Reducing total indirect ownership to 3,561,655 shares.
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in cash and backed by top-tier life science venture capital firms. The cystic fibrosis therapeutics market is projected to grow at a 14.2% CAGR, reaching $22.8 billion by 2030, offering significant market potential.
